Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study Evaluating the Safety and Efficacy of Autologous Peripheral Blood Hematopoietic Stem and Progenitor Cells (CS-101) Modified by Ex Vivo Base Editing to Induce γ-Globin Production in Treating Patients With β-Thalassemia

NCT06328764 is registered in ClinicalTrials.gov with CorrectSequence Therapeutics Co., Ltd as lead sponsor.

NCT NCT06328764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06328764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study Evaluating the Safety and Efficacy of Autologous Peripheral Blood Hematopoietic Stem and Progenitor Cells (CS-101) Modified by Ex Vivo Base Editing to Induce γ-Globin Production in Treating Patients With β-Thalassemia
Lead sponsor
CorrectSequence Therapeutics Co., Ltd
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
March 19, 2024
Completion date
July 31, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

beta-thalassemia